Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis.

Trial Profile

Phase 1-2 Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer; Carcinomatous meningitis
  • Focus Adverse reactions
  • Acronyms HIT
  • Most Recent Events

    • 02 Nov 2017 Planned primary completion date changed from 1 Sep 2017 to 1 May 2018.
    • 25 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top